Atorvastatin (CI-981) clinical pharmacokinetic study (I) - Relative bioavailability of amorphous and crystalline preparations of atorvastatin -

Japanese Pharmacology and Therapeutics

Volumn 26, Issue 8, 1998, Pages 67-78

  Oishi, Shimako ^a   Watanabe, Takashi ^a   Higuchi, Saburo ^a   Matsumura, Masami ^a   Kikawa, Yoshio ^a   Toyoki, Takaaki ^b   Itoh, Seikei ^b   Suzuki, Masahiko ^b   Kitamura, Fumihiko ^b   Oohira, Tetsuya ^b   Suzuki, Kenji ^b   Sehata, Katsuyuki ^b   Naitoh, Yoshihiko ^b  

^a Yamanouchi Pharmaceutical Co Ltd

^b Kan nondai Clinic

Author keywords

Amorphous; Atorvastatin; Bioavailability; CI 981; Clinical pharmacokinetics; Crystalline; HMG CoA reductase inhibitor; Lipid regulator

Indexed keywords

ATORVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

EID: 7344260722     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Baumann KL et al: The convergent synthesis of CI-981. an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 33 : 2283-2284, 1992
2. CI-981 (Atorvastatin) 14 : 1559-1584, 1998
3. CI-981 (Atorvastatin) 14 : 1601-1611, 1998
4. CI-981 (Atorvastatin) 14 : 1613-1622, 1998
5. CI-981 (Atorvastatin) 14 : 1585-1600, 1998
6. CI-981 (Atorvastatin) 14 : 1623-1628, 1998
7. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group : Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 79 : 1248-1252, 1997
8. Gibson DM et al : A single-dose bioavailability study comparing 10 mg atorvastatin tablets prepared from a crystalline I lot to 10 mg atorvastatin tablets (amorphous B) used in protocol 981-008. Warner-Lambert Company, Parke-Davis Pharmaceuticals No. RR744 00208, Ann Arbor, Michigan, USA, 1995
9. : LC-MS/MS Atorvastatin 4: 102, 1997
10. : CI-981 10 mg in vitro : Amorphous B Crystalline No. D9703272-1, 1997
11. Noyes AA, Whitney WR: The rate of solution of solid substances in their own solutions. J Am Chem Soc 19 : 930, 1897
12. Gibaldi M: Chapter 4 Gastrointestinal Absorption-Physicochemical Considerations- in Biopharmaceutics and Clinical Pharmacokinetics. 3rd ed, p 44-63, Lea & Febiger, Philadelphia, 1984
13. McInnes GT et al : Effect of micronization on the bioavailability and pharmacologic activity of spironolactone. J Clin Pharmacol 22 : 410-417, 1982
14. Terhaag B et al : The in vitro liberation and the bioavailability of different brands of griseofulvin in plasma and urine in man. Int J Clin Pharmacol Ther Toxicol 23 : 475-479, 1985